Sign in

    Sebastian Sandler • JPMorgan Chase & Co.

    Sebastian Sandler's questions to Adaptive Biotechnologies Corp (ADPT) leadership

    Sebastian Sandler's questions to Adaptive Biotechnologies Corp (ADPT) leadership • Q2 2025

    Question

    Sebastian Sandler, on behalf of JPMorgan Chase & Co., asked about the impact of the recent NCCN guideline update on multiple myeloma ordering patterns and how unique patient IDs translate to future MRD testing. He also inquired about the MRD Pharma backlog conversion to revenue and any changes in pharma customer behavior.

    Answer

    CCO Susan Bobulsky stated the NCCN update is a supportive tailwind, reinforcing their message in the community, but it's too early to attribute specific volume increases to it. CFO Kyle Piskel noted the pharma backlog conversion profile is largely unchanged. CEO Chad Robins added that global regulatory support for MRD as an endpoint (ODAC, CHMP) is growing, making them bullish on the pharma opportunity with minimal impact from other macro factors.

    Ask Fintool Equity Research AI

    Sebastian Sandler's questions to Adaptive Biotechnologies Corp (ADPT) leadership • Q1 2025

    Question

    Sebastian Sandler, on behalf of Rachel Vatnsdal from JPMorgan Chase & Co., questioned if the strong sequential increase in clonoSEQ volume is a sustainable run-rate and asked if community setting growth is from new or existing accounts.

    Answer

    Executive Susan Bobulsky expressed confidence in continued sequential growth for the year but remained prudent about the exact magnitude each quarter due to new initiatives launching in the second half. She confirmed that growth in the community setting was driven by both acquiring new accounts and achieving deeper penetration within existing ones.

    Ask Fintool Equity Research AI

    Sebastian Sandler's questions to ICON PLC (ICLR) leadership

    Sebastian Sandler's questions to ICON PLC (ICLR) leadership • Q2 2025

    Question

    Sebastian Sandler, on for Casey Woodring of JPMorgan Chase & Co., asked about ICON's role in licensing deals between large pharma and Chinese biotechs, and what percentage of ICON's revenue comes from China.

    Answer

    CEO Steve Cutler stated that revenue from China is approximately 3%. He explained that while Chinese biotechs use local CROs for domestic trials, they rely on global organizations like ICON for international trials aimed at US and European registration. He views this as a 'medium to longer-term fuel' for the business as Chinese innovation grows.

    Ask Fintool Equity Research AI